New drug interaction study launches for elecoglipron and statins

NCT ID NCT07534592

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Apr 20, 2026 · Last updated Apr 30, 2026 · Updated 2 times

Summary

This early-stage study will look at how a new drug called elecoglipron changes the way the body processes two common cholesterol-lowering medications (atorvastatin and rosuvastatin). About 40 healthy volunteers will take the drugs in a fixed order, and researchers will measure drug levels in the blood. The goal is to understand if elecoglipron affects how these statins work, which is important for future safe use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    Glendale, California, 91206, United States

  • Research Site

    Brooklyn, Maryland, 21225, United States

Conditions

Explore the condition pages connected to this study.